Axonics to Present its Sacral Neuromodulation System at the International Neuromodulation Society 12th World Congress in Montreal

IRVINE, Calif.--()--Axonics Modulation Technologies, Inc., a developer of a novel implantable Sacral Neuromodulation System (SNM) for the treatment of urinary and fecal dysfunction, announced today that it has been selected to present its technology advancements during the Innovations in Neuromodulation session at the International Neuromodulation Society congress on Saturday, June 6, 2015 at the Fairmont Queen Elizabeth Hotel in Montreal, Quebec, Canada.

About Overactive Bladder, Fecal Incontinence and the SNM market

Overactive Bladder (OAB) is a condition characterized by a sudden need to urinate caused by abnormal bladder storage function that can lead to incontinence episodes. It is also often associated with a high frequency of daily voids. Approximately 85 million adults in the US and Europe have OAB symptoms, and another 40 million are reported to suffer from Fecal Incontinence (FI). OAB significantly affects quality of life and frequently results in depression, social isolation, and dramatic life-style alteration. This condition costs an estimated $66 billion every year in the US, including direct and indirect costs. SNM therapy is approved in Europe and the US for the treatment of urgency and frequency, urinary incontinence, urinary retention and FI. OAB and FI treatment via SNM has been proven to be a safe, effective, durable and reversible solution supported by dozens of peer-reviewed publications. It has a demonstrated clinical superiority to standard medical therapy and OAB patients who receive SNM have also reported significantly higher quality of life than patients under drug treatment. The American Urological Association and the American College of Gastroenterology recommend SNM for patients who have not responded to standard behavioral and drug therapy.

About the Axonics Sacral Neuromodulation System™

The Axonics SNM System is an implantable system that modulates sacral nerve activity for the management of chronic intractable urinary and fecal dysfunction. The System includes, among other innovations, a miniaturized rechargeable implantable pulse generator that is 60% smaller and promises to last over a decade longer in the body than the only other marketed device for OAB and FI.

About the International Neuromodulation Society (INS) and the 12th World Congress

The INS is a nonprofit group of clinicians, scientists and engineers dedicated to the scientific development and awareness of neuromodulation – the alteration of nerve activity through the delivery of electrical stimulation or chemical agents to targeted sites of the body. Founded in 1989 and based in San Francisco, CA, the INS educates and promotes the field through meetings, its MEDLINE-indexed, peer-reviewed journal Neuromodulation: Technology at the Neural Interface, and chapter websites.

The 12th World Congress of the INS is expected to bring clinicians, scientists, bioengineers and members of Industry from all five continents with attendance expected to surpass 1,300.

About Axonics Modulation Technologies, Inc.

Axonics, based in Irvine, CA, is a privately held venture-backed pre-revenue company developing a novel implantable neuromodulation technology licensed from The Alfred Mann Foundation directed toward a number of clinical indications. Investors include Paris-based Edmond de Rothschild Investment Partners, NeoMed Management based in Jersey, Channel Islands, Legend Capital, based in Beijing, China and The Alfred E. Mann Foundation, a non-profit medical research organization based in Valencia, CA. For more information, visit the Company’s website at www.axonicsmodulation.com.

Contacts

Axonics Modulation Technologies, Inc.
Dan Dearen, 949-396-6322
Chief Operating & Financial Officer

Contacts

Axonics Modulation Technologies, Inc.
Dan Dearen, 949-396-6322
Chief Operating & Financial Officer